Current Affairs · · GS2 · Social Justice

Essential medicine pricing: why trade margins are under scrutiny

The Supreme Court has questioned steep gaps between the price paid by retailers and the MRP charged to patients for some medicines. The issue exposes a policy gap: scheduled medicines face direct price ceilings, while large trade margins can persist elsewhere, affecting patients and taxpayers.

Event date:

REq1
  1. Context1 / 6
    • The Supreme Court has questioned large mark-ups between the Price to Retailer (PTR) and the Maximum Retail Price (MRP) of some medicines.
    • The Bench discussed a cancer medicine supplied to retailers for about ₹2,700 that carries an MRP of ₹27,000.
    • It asked why the 16% retailer margin used in working out ceiling prices for scheduled medicines should not guide wider price regulation.
    • The Court raised a further concern. Inflated hospital medicine prices can also raise costs met through government-funded health schemes, and so by taxpayers.

    The core issue. A medicine may carry an MRP on its pack, but that figure does not show how much of the price comes from making the medicine, moving it, or the trade margins added along the way.

  2. Note2 / 6

    How India regulates medicine prices

    India controls drug prices mainly through the Drugs (Prices Control) Order, 2013, known as the DPCO. The National Pharmaceutical Pricing Authority (NPPA) puts that framework into practice.

    The table below sets out the four ways a medicine's price may be treated.

    CategoryPrice ruleUPSC point
    Scheduled medicinesNPPA fixes a ceiling priceMainly medicines in Schedule-I, drawn from the National List of Essential Medicines (NLEM)
    Non-scheduled medicinesNo routine ceiling price set in advanceMRP normally cannot rise by more than 10% in 12 months
    Special interventionNPPA can step in in the public interestPara 19 allows price action in extraordinary circumstances
    42 selected anti-cancer drugs30% trade-margin cap, introduced in 2019The main example of Trade Margin Rationalisation

    The ceiling price of a scheduled formulation is worked out from the average Price to Retailer of qualifying brands, with a 16% retailer margin added.

    For non-scheduled medicines, NPPA mainly watches prices and limits how much the MRP can rise in a year.

  3. Key concepts3 / 6

    1. Price to Retailer (PTR)

    PTR is the price at which a retailer obtains the medicine, before selling it to the patient.

    2. Maximum Retail Price (MRP)

    MRP is the highest price that can legally be charged to the consumer. It is the figure printed on the pack.

    A wide gap between PTR and MRP leaves room for a large trade margin.

    3. Trade Margin Rationalisation (TMR)

    A trade margin is the difference added across the distribution chain before a medicine reaches the patient.

    NPPA used TMR in 2019 for 42 non-scheduled anti-cancer medicines. The step brought prices down across hundreds of brands.

    4. NLEM and scheduled medicines

    The National List of Essential Medicines (NLEM) sets out the medicines treated as important for India's health needs.

    Medicines placed in Schedule-I of the DPCO come under NPPA's direct ceiling-price system.

    A common trap. A non-scheduled medicine is not free of all regulation. Its price is watched, and its yearly rise is capped. But it does not face the routine ceiling-price system.

  4. Note4 / 6

    Why public spending also matters

    High medicine mark-ups affect more than the individual patient.

    Patient burden

    A patient may pay far more than the price at which the hospital or the retailer obtained the medicine.

    Captive hospital pharmacies

    The Supreme Court also questioned arrangements where patients must buy medicines from a hospital's own pharmacy. This can cut price competition.

    Taxpayer burden

    When government-funded health schemes pay for expensive hospital treatment, inflated medicine charges can push up public spending.

    Why pooled procurement helps

    Governments can bargain on price by buying large quantities together, instead of buying through many separate channels.

    One customer has little bargaining power. Ten thousand customers negotiating together can demand a better price.

    This is why pooled procurement, open tendering and negotiated prices can work alongside retail price control.

  5. Way forward5 / 6
    • Target excessive margins. Extend evidence-based trade-margin regulation where wide PTR–MRP gaps persist.
    • Improve price transparency. Make the build-up of a price easier for regulators, hospitals and patients to examine.
    • Use pooled procurement. Government programmes can negotiate prices directly, instead of relying only on the printed MRP.
    • Strengthen competition. Patients should not be forced without good reason to buy only from an in-house pharmacy.
    • Protect availability. Price control must still leave manufacturing viable. Prices pushed too low can create shortages, as recent cancer-drug cases have shown.

    The final takeaway. The policy question is not "should medicines be cheap?" It is "how can India curb excessive margins without shrinking the supply of essential medicines?"

  6. Note6 / 6
    REq1

Sources

  • The Hindu · Top court flags steep mark-ups on essential drugs, p. 1, 12 · 30 September 2026
  • The Indian Express · p. 17 · 30 September 2026
  • National Pharmaceutical Pricing Authority · Drugs (Prices Control) Order, 2013 and proactive disclosure: ceiling-price method and the 16% retailer margin · 15 May 2013
  • Press Information Bureau, Department of Pharmaceuticals · Affordability of Medicines: scheduled and non-scheduled drug price rules · 20 March 2026
  • Press Information Bureau · Trade Margin Rationalisation for 42 selected non-scheduled anti-cancer medicines: 30% cap · 27 February 2019
  • Bar and Bench · Kishan Chand Jain v. Union of India: proceedings on drug price mark-ups · 29 September 2026

Syllabus

PaperSubjectSub-topic
GS2Social JusticeHealth: government policies and interventions; affordability and access to healthcare
GS3EconomyPharmaceutical sector; regulation; inclusive growth
PrelimsGovernanceDPCO 2013, NPPA, NLEM; scheduled and non-scheduled medicines

Topics

IndustryPublic FinanceGovernanceNon-Constitutional BodiesHealth

Practice questions

  1. With reference to drug-price regulation in India, consider the following statements: 1. NPPA fixes ceiling prices for scheduled formulations under the DPCO, 2013. 2. Non-scheduled medicines are completely outside price regulation. 3. The NLEM is relevant to identifying medicines brought under scheduled price control. Which of the statements given above are correct?

    1. 1 only
    2. 1 and 2 only
    3. 1 and 3 only
    4. 1, 2 and 3
    Show answer

    Answer: C. Statements 1 and 3 are correct. Statement 2 is incorrect: non-scheduled medicines are monitored, and their MRP normally cannot rise by more than 10% in 12 months, so they are regulated even though no ceiling price is fixed in advance.

    Difficulty: medium · statement

  2. Trade Margin Rationalisation, as used in Indian drug-price policy, is primarily aimed at which one of the following?

    1. Fixing doctors' consultation charges
    2. Controlling pharmaceutical patents
    3. Limiting excessive margins between supply-chain prices and final medicine prices
    4. Regulating clinical trials
    Show answer

    Answer: C. Trade Margin Rationalisation caps the margin added between the price at which a medicine is supplied and the price finally charged to the patient. NPPA used this approach in 2019 for 42 selected non-scheduled anti-cancer medicines, applying a 30% trade-margin cap.

    Difficulty: easy · statement

  3. Which one of the following bodies implements medicine-price regulation under the Drugs (Prices Control) Order, 2013?

    1. Central Drugs Standard Control Organisation
    2. Indian Council of Medical Research
    3. National Pharmaceutical Pricing Authority
    4. National Medical Commission
    Show answer

    Answer: C. The National Pharmaceutical Pricing Authority implements the DPCO, 2013, fixing ceiling prices for scheduled formulations and monitoring the prices of non-scheduled medicines. The Central Drugs Standard Control Organisation is the drug regulator for quality and approvals, the Indian Council of Medical Research is a research body, and the National Medical Commission regulates medical education and practice.

    Difficulty: easy · statement

Mains practice

Answer-writing practice on this article. Attempt it first, then open the hints.

  1. GS2 · 250 words

    Examine the challenges in ensuring affordable medicines in India while maintaining adequate incentives for pharmaceutical production.

    Show hints
    1. Set out the affordability problem: high out-of-pocket spending on medicines and the burden of a wide gap between the price to the retailer and the printed MRP.
    2. Explain the existing tools: ceiling prices for scheduled formulations under the DPCO, the annual cap on price rises for non-scheduled medicines, and the power to intervene in the public interest.
    3. Argue the producer side: price control that is too tight can make manufacturing unviable and cause shortages, as recent cancer-drug cases show.
    4. Discuss the distribution chain, where trade margins rather than production costs may be driving the final price.
    5. Conclude with a balance: targeted trade-margin regulation, price transparency and pooled procurement rather than across-the-board price cuts.
  2. GS3 · 150 words

    How can trade-margin regulation and pooled procurement complement conventional drug-price ceilings?

    Show hints
    1. Explain the limit of a ceiling price: it applies mainly to scheduled formulations and leaves wide margins possible elsewhere.
    2. Show how capping the trade margin attacks the distribution mark-up directly, citing the 2019 intervention on 42 anti-cancer medicines.
    3. Explain how buying in bulk shifts bargaining power to the government and sets a price independent of the printed MRP.
    4. Conclude that the three tools cover different parts of the price build-up and work best together, with transparency to identify where margins are excessive.